The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model.
The aim of this article was to study the effect of dual drug-eluting stent (DES) on both restenosis and thrombosis in a porcine coronary artery model. This study reports on the use of two drugs coated on the stent to simultaneously minimize both restenosis and thrombosis. The DES was prepared by spray coating a bare metal stent with a biodegradable polymer loaded with sirolimus and triflusal, to treat against restenosis and thrombosis, respectively. The two-layered dual drug-coated stent was characterized in vitro for surface properties before and after expansion, as well as for possible delamination by cross-sectioning the stent in vitro. In vivo animal studies (in a pig model) were then performed for acute thrombosis, inflammation, and restenosis. The results show a significant reduction in restenosis with a stent coated with both drugs compared with the controls (a bare metal stent, a sirolimus-coated, and a pure polymer-coated stent). The reduction in restenosis with a sirolimus/triflusal-eluting stent is associated with an inhibition of inflammation and thrombus formation, suggesting that such dual DES have a role to play for the treatment of coronary artery diseases.
Huang
Yingying
Y
School of Materials Science and Engineering, Nanyang Technological University, Singapore, Singapore.
Venkatraman
Subbu S
SS
Boey
Freddy Y C
FY
Umashankar
P R
PR
Mohanty
Mira
M
Arumugam
Sabareeswaran
S
D000818:Animals; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation; D002858:Chromium Alloys / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000517:prevention & control / Q000601:surgery*; D003331:Coronary Vessels / Q000187:drug effects / Q000601:surgery*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011474:Prosthesis Design; D012459:Salicylates / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D013552:Swine; D013927:Thrombosis / Q000209:etiology*; D016896:Treatment Outcome
D002858:Chromium Alloys; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D012459:Salicylates; C016167:triflusal; D020123:Sirolimus